Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer
about
Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment.Predictors of preoperative MRI for breast cancer: differences by data source.Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused updateSexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors.Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms.CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy.Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL)Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review.Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors.Providers of follow-up care in a population-based sample of breast cancer survivors.Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review.Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?Endocrine therapy adherence: a cross-sectional study of factors affecting adherence and discontinuation of therapy.Adjuvant endocrine therapy for the surgeon: options, side effects, and their management.Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer.Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.Women with breast cancer report substantially more disease- and treatment-related side or late effects than registered by clinical oncologists: a cross-sectional study of a standard follow-up program in an oncological department.Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study.Endocrine therapy for breast cancer in the primary care settingImproving adherence to endocrine hormonal therapy among breast cancer patients: Study protocol for a randomized controlled trial
P2860
Q27331637-F9F2C0BF-7659-444F-94C9-F7B30BB40AD6Q30948683-D41FB775-8C88-431D-90E7-AFFDF2904E83Q34421634-8274FEE1-CF72-45D0-AB7D-4AC36F5F17D1Q35207952-892092D1-D0A2-4CB9-955F-599BC78D7FFCQ35490056-E6D2D340-6D8B-4A33-B2AC-A67D6BE1D993Q35845258-A59AA033-59BE-4875-8E3C-45C601762618Q36688742-F88AF0B7-C27F-4D65-9DDD-9FD4FD3BC450Q36901989-2CBAF46A-B636-49BC-A308-54B19107657CQ37130218-8624B55E-30CE-4BD9-B547-AC9F7A3CE557Q37669380-883FF973-4DEE-406E-9B4D-D39CCEFD0E73Q37704897-4416A7F8-CD28-44D2-B7ED-98A8B0DFE890Q37709416-AD3C0213-1363-4281-86A0-FB2555C44368Q38876325-F0B09A23-C636-4BA2-A72E-74B04336C2DCQ39117032-39D54037-62DA-4101-B4BD-3D20AB5FF9C2Q40498040-98792B7A-A75F-4DB4-AF42-2B5C08A73AE7Q40942814-035A04B4-4C5C-4D1D-9421-584BB407CE30Q46661254-ECFD6E1C-FEC5-4E24-8046-E698BFBCBACEQ46838843-3580C99D-5389-406A-962A-4E84C4DE4330Q47187808-8B83A6C0-B794-44FE-A7B9-BF01ACEDB6C3Q47624971-2A9D369E-B439-430B-86A9-E0107E012F4AQ47728067-9677C5DE-4693-4FE1-B5EF-4F5E0922D9B4Q48250658-301FC84A-713C-47BB-B73C-B6A27AA93D18Q57108564-64BE2F2A-7F06-4BC9-8B06-4F937E0431E7Q58121493-F225B71D-E45F-4086-9490-25E282DEF262
P2860
Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Patient-reported discontinuati ...... with early-stage breast cancer
@ast
Patient-reported discontinuati ...... with early-stage breast cancer
@en
type
label
Patient-reported discontinuati ...... with early-stage breast cancer
@ast
Patient-reported discontinuati ...... with early-stage breast cancer
@en
prefLabel
Patient-reported discontinuati ...... with early-stage breast cancer
@ast
Patient-reported discontinuati ...... with early-stage breast cancer
@en
P2093
P2860
P356
P1476
Patient-reported discontinuati ...... with early-stage breast cancer
@en
P2093
Denise M Boudreau
Diana S M Buist
Erin J Aiello Bowles
Janet Chestnut
Jessica Chubak
Monica Fujii
P2860
P304
P356
10.1200/JOP.2012.000543
P407
P577
2012-07-17T00:00:00Z